Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis

Summary

The incidence of intra-abdominal candidiasis is increasing, and it is now the leading indication for antifungal therapy, ahead of candidemia. Prospective randomized trials of antifungal therapy have almost exclusively concerned patients with candidemia and did not include patients with intra-abdominal infections. The aim of this study is to demonstrate that caspofungin antifungal therapy for intra-abdominal candidiasis in ICU patients is associated with lower failure rate compared to placebo.

Timeline

Start

2019-01-01

Primary completion

2024-10-04

Completion

2024-12-04

Drugs

Indications